Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective therapy for hematological malignancies and inherited diseases. However, acute graft-versus-host-disease (aGVHD) is a major life-threatening complication after allo-HCT and there are few therapeutic options for severe steroid-refractory aGVHD. Preliminary studies on cotransplantation of mesenchymal stem cells (MSCs) have shown an improvement in or resolution of severe aGVHD. However, the underlying mechanism this immunosuppressive effect has not been elucidated. Most of the data suggest that this immunosuppressive effect involves soluble factors such as IL-6 or TGF-β as well as cell-cell contact dependence. MSCs interact either directly with T cells or indirectly via other immune cells such as dendritic cells and NK cells. Here we review the immunomodulatory function of MSCs in allo-HCT and their potential usefulness in the treatment or prevention of severe acute GVHD.
Keywords: Mesenchymal stem cells (MSCs), acute graft-versus-host disease (aGVHD), allogeneic hematopoietic cell transplantation (Allo-HCT), steroid-refractory acute GVHD
Current Stem Cell Research & Therapy
Title: Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus- Host Disease After Allogeneic Hematopoietic Cell Transplantation
Volume: 4 Issue: 4
Author(s): Tomomi Toubai, Sophie Paczesny, Yusuke Shono, Junji Tanaka, Kathleen P. Lowler, Chelsea T. Malter, Masaharu Kasai and Masahiro Imamura
Affiliation:
Keywords: Mesenchymal stem cells (MSCs), acute graft-versus-host disease (aGVHD), allogeneic hematopoietic cell transplantation (Allo-HCT), steroid-refractory acute GVHD
Abstract: Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective therapy for hematological malignancies and inherited diseases. However, acute graft-versus-host-disease (aGVHD) is a major life-threatening complication after allo-HCT and there are few therapeutic options for severe steroid-refractory aGVHD. Preliminary studies on cotransplantation of mesenchymal stem cells (MSCs) have shown an improvement in or resolution of severe aGVHD. However, the underlying mechanism this immunosuppressive effect has not been elucidated. Most of the data suggest that this immunosuppressive effect involves soluble factors such as IL-6 or TGF-β as well as cell-cell contact dependence. MSCs interact either directly with T cells or indirectly via other immune cells such as dendritic cells and NK cells. Here we review the immunomodulatory function of MSCs in allo-HCT and their potential usefulness in the treatment or prevention of severe acute GVHD.
Export Options
About this article
Cite this article as:
Toubai Tomomi, Paczesny Sophie, Shono Yusuke, Tanaka Junji, Lowler P. Kathleen, Malter T. Chelsea, Kasai Masaharu and Imamura Masahiro, Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus- Host Disease After Allogeneic Hematopoietic Cell Transplantation, Current Stem Cell Research & Therapy 2009; 4 (4) . https://dx.doi.org/10.2174/157488809789649269
DOI https://dx.doi.org/10.2174/157488809789649269 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Busulfan Use in Hematopoietic Stem Cell Transplantation: Pharmacology, Dose Adjustment, Safety and Efficacy in Adults and Children
Current Drug Safety The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry Multi- and Inter-Disciplinary Science in Personalized Delivery of Stem Cells for Tissue Repair
Current Stem Cell Research & Therapy Novel Oral Anticoagulants in the Management of Polycythemia Vera and Essential Thrombocythemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Current Pharmaceutical Design Synthesis, Antifungal Evaluation and Molecular Docking Studies on 2- thioxoimidazolidin-4-one Derivatives
Medicinal Chemistry Proteasome Structure, Function, and Lessons Learned from Beta-Lactone Inhibitors
Current Topics in Medicinal Chemistry Discovery and Advancement of Farnesyl Transferase Inhibitors as Potential Anticancer Therapeutic Agents: SCH 66336 a Case Study
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Editorial [Hot Topic: New Perspectives in the Treatment of Hematological Malignancies (Guest Editor: Masahiro Kizaki)]
Current Pharmaceutical Biotechnology Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Animal Models for Growth Hormone Gene Therapy
Current Gene Therapy